Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Weis, Sebastian ^a   Franke, Annegret ^a   Mössner, Joachim ^a   Jakobsen, Janus C ^b   Schoppmeyer, Konrad ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Rigshospitalet   (Denmark)

^c Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BURN; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CHOLANGITIS; CLINICAL EFFECTIVENESS; CRYOABLATION; DISEASE SEVERITY; EVENT FREE SURVIVAL; HEALTH CARE COST; HUMAN; LENGTH OF STAY; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER ISCHEMIA; LIVER RESECTION; LIVER TRANSPLANTATION; MICROWAVE THERMOTHERAPY; MORTALITY RISK; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN ABSCESS; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CATHETER ABLATION; INTRADERMAL DRUG ADMINISTRATION; LIVER TUMOR; META ANALYSIS; METHODOLOGY; MICROWAVE RADIATION; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETIC ACID; ALCOHOL;

ACETIC ACID; ADMINISTRATION, CUTANEOUS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; ETHANOL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MICROWAVES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84897368240     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003046.pub3     Document Type: Review

References (112)

1. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al.Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scandinavian Journal of Gastroenterology 2008;43:727-35.
2. Chen MS, Li JQ, Zheng Y, Go RP, Liang HH, Zhang YQ, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of Surgery 2006;243(3):321-8.
3. Feng K, Yan J, Li X, Ma K, Wang S, Bie P, et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology 2012;57(4):794-802.
4. Ferrari FS, Mgliola A, Scorzelli A, Stella A, Vigni F, Drudi FM, et al.Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. La Radiologia Medica 2007;112(3):377-93.
5. Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, et al.Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Research 2011;31(6):2291-5.
6. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Annals of Surgery 2010;252(6):903-12.
7. Lencioni R, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al.Small hepatocellular carcinoma: randomized comparison of radio-frequency thermal ablation and percutaneous ethanol injection. Radiology 2003;228:235-40.
8. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YG. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology 2004;127:1714-23.
9. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YG. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm. Gastroenterology 2004;127:1714-23.
10. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54(8):1151-6.
11. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54(8):1151-6.
12. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al.Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002;223:331-7.
13. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al.A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129(1):122-30.
14. Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al.Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver International 2004;24(6):625-9.
15. Amarnath S, Griffith KA, Higgins E, Lawrence TS, Rubin J, Pan CC. Comparison of patients with hepatocellular carcinoma (HCC) treated with external beam radiotherapy (EBRT) or radiofrequency ablation (RFA). International Journal of Radiation Oncology, Biology, Physics 2006;66(3 Suppl):1071.
16. Buscarini L, Di Stasi M, Buscarini E, Fornari F, Squassante L, Rossi S, et al.Clinical presentation, diagnostic work-up and therapeutic choices in two consecutive series of patients with hepatocellular carcinoma. Oncology 1996;53(3):204-9.
17. Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Zheng Y. Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency alone for small hepatocellular carcinoma. Chinese Journal of Oncology 2005;27(10):623-5.
18. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al.Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. Journal of the American Medical Association 2008;299(14):1669-77.
19. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010;51(4):1116-8.
20. Cuschieri A, Bracken J, Boni L. Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumours. Endoscopy 1999;31(4):318-21.
21. Gan YH, Yie SH, Ren ZG, Xia JL, Zhang BH, Wang YH, et al.Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma. Chinese Journal of Oncology 2004;26(8):496-8.
22. Giorgio A, Farella N, Di Sarno A, Scognamiglio U, De Stefano G, De Rogatis A, et al.Western trial comparing percutaneous radiofrequency of both hepatocellular carcinoma and the portal venous tumor thrombus plus sorafenib with sorafenib alone. Journal of Hepatology 2011;54(Suppl 1):S542.
23. Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al.Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?. Journal of Vascular & Interventional Radiology 1998;9(1):101-11.
24. Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, et al.Radiofrequency ablation versus surgical resection for the treatment of early stage hepatocellular carcinoma (HCC) - a large multicentre study. Journal of Hepatology 2012;56(Suppl 2):S392-S393.
25. Jiao LR, Hansen PD, Havlik R, Mitry RR, Pignatelli M, Habib N. Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. American Journal of Surgery 1999;177(4):303-6.
26. Khan MR, Poon RTP, Ng KK, Chan ACC, Yuen J, Tung H, et al.Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Archives of Surgery 2007;142(12):1136-43.
27. Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Sezaki H, Yatsuji H, et al.Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome. Liver International 2007;27(3):353-9.
28. Kurokohchi K, Watanabe S, Masaki T, Hosomi N, Himoto T, Kimura Y, et al.Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma. World Journal of Gastroenterology 2005;11(10):1426-32.
29. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210(3):655-61.
30. Lü MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al.Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. National Medical Journal of China 2006;86(12):801-5.
31. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010;116(23):5452-60.
32. Morimoto M, Numata K, Kondo M, Nozaki A, Moriya S, Takizawa K, et al.Long-term outcome in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial to determine the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Hepatology 2011;54(Suppl S1):1366A.
33. Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al.Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. Journal of Gastroenterology and Hepatology 2009;24:223-7.
34. Opocher E, Barabino M, Costa M, Zuin M, Carnevali P, Santambrogio R. The impact of radiofrequency ablation and liver resection on patients with cirrhosis and early and very early hepatocellular carcinoma. HPB 2010;12(Suppl S1):69.
35. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen M. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012;262(2):689-700.
36. Santambrogio R, Kluger M, Costa M, Belli A, Laurent A, Zuin M, et al.Hepatic resection versus laparoscopic radiofrequency ablation for "very early" hepatocellular carcinoma. Digestive and Liver Disease 2012;44(Suppl 1):S9-S10.
37. Sreenivasan K, Roy S, Subramaniam M. Comparison of radiofrequency ablation versus resection for the treatment of hepatocellular carcinoma. HPB 2010;12(Suppl S1):164.
38. Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, et al.Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. Journal of Hepato-Biliary-Pancreatic Surgery 2009;16:359-66.
39. Zhang FJ, Wu PH, Zhao M, Gu YK, Zhang L, Tan ZB. Evaluation of combined percutaneous radio-frequency ablation and percutaneous ethanol injection after transcatheter arterial chemoembolization for hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2005;27(4):248-50.
40. Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al.Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007;244(2):599-607.
41. Di Costanzo GG, Tortora R, D'Adamo G, Galeota Lanza A, Carannante N, Lampasi F, et al.Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial. Journal of Hepatology 2011;54(Suppl 1):S254-S255.
42. Kuansheng M, Feng K, Yan J, Wang S, Bie P. A randomized controlled study of radiofrequency ablation and surgical resection for early-stage hepatocellular carcinomas less than 4 cm in diameter. Hepatology 2011;54(S1):418A.
43. NCT00814242 . Hepatectomy versus radiofrequency ablation for hepatocellular carcinoma adjacent to major blood vessels. clinicaltrials.gov/ct2/show/NCT00814242 (accessed 16 December 2013).
44. Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. Journal of Gastrointestinal Surgery 2008;12(9):1521-6.
45. Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma. Lancet 1999;353(9165):1676-7.
46. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al.Results of surgical and nonsurgical treatment for hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 2000;32:1224-9.
47. Bismuth H, Majno PE. Hepatobiliary surgery. Journal of Hepatology 2000;32:208-24.
48. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
49. Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterology 2009;9:31.
50. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61:763-9.
51. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98.
52. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology 2001;35:421-30.
53. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
54. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality of cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 2003;348:1625-38.
55. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49(2):453-9.
56. Copenhagen Trial Unit. TSA - trial sequential analysis, 2011. ctu.dk/tsa/ (accessed 16 December 2013).
57. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al.Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Annals of Surgery 1999;230(1):1-8.
58. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
59. Dubay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, et al.Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB 2011;13(1):24-32.
60. European Association for the Study of the Liver, European Organisation for Research and Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012;56(4):908-43.
61. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine 1999;340:745-50.
62. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8.
63. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76.
64. Francia G, Marone G. Ultrasound guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with 'cooled-tip needle'. A preliminary clinical experience. European Journal of Ultrasound 1999;9:145-53.
65. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 3. Art. No.: LIVER.
66. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American Journal of Roentgenology 2000;174(2):323-31.
67. Grasso A, Watkinson AF, Tibballs JM, Burroughs AK. Radiofrequency ablation in the treatment of hepatocellular carcinoma - a clinical viewpoint. Journal of Hepatology 2000;33:667-72.
68. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
69. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
70. Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, et al.Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatology Research 2005;33(3):241-9.
71. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. International Journal of Cancer 2007;121(7):1624-6.
72. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
73. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Annals of Surgery 2009;249(1):20-5.
74. Lencioni R, Pinto F, Bassi AM, Moretti M, Di Giulio M, Marchi S, et al.Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: an European experience. European Radiology 1997;7:514-9.
75. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolodi L, et al.Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197(1):101-8.
76. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al.Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214(3):761-8.
77. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al.Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8.
78. Llovet JM, Bruix J, the Barcelona-Clínic Liver Cancer Group. Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
79. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
80. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008;359(4):378-90.
81. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: ]
82. Machin D, Stenning SP, Parmar MK, Fayers PM, Girling DJ, Stephens RJ, et al.Thirty years of Medical Research Council randomized trials in solid tumours. Clinical Oncology 1997;9:100-14.
83. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996;334:693-9.
84. Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: current status. World Journal of Gastroenterology 2010;2(11):417-24.
85. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
86. Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. American Journal of Surgery 2009;198(3):396-406.
87. Nicoli N, Casaril A, Marchiori L, Mangiante G, Marini G, Colombardi R. Intraoperative and percutaneous radiofrequency thermal ablation in the treatment of hepatocellular carcinoma. Chirurgia Italiana 2000;52:29-40.
88. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.
89. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: ]
90. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
91. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
92. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al.Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. American Journal of Roentgenology 1996;167(3):759-68.
93. Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, et al.Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. American Journal of Roentgenology 1998;170(4):1015-22.
94. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
95. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
96. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
97. Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: ]
98. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408-12.
99. Sørensen HT, Mellemkjær L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al.Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. Journal of Clinical Gastroenterology 2003;36:356-9.
100. Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?. Liver Transplantation 2000;6:67-72.
101. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
102. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
103. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 16 December 2013).
104. Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013; Vol. in press.
105. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
106. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
107. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
108. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al.Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver disease. Journal of Clinical Gastroenterology 2009;43(5):389-90.
109. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al.Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology 2010;10:78.
110. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Protocol]. The Cochrane Library (Update Software, Oxford) 2001, Issue 2.
111. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Review]. The Cochrane Library (Update Software, Oxford) 2002, Issue 3.
112. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: ]